Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Orilissa elagolix CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Keytruda Pembrolizumab CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Lynparza Olaparib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Viibryd vilazodone Depression, Major depressive disorder CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Imbruvica ibrutinib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Revolade eltrombopag CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Symdeko tezacaftor/ivacaftor CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
TBC etonogestrel Prevention of pregnancy Withdrawn
Tecentriq Atezolizumab Withdrawn
Oncaspar pegaspargase Adult Acute Lymphocytic Leukemia (ALL) Unable to recommend reimbursement Not filed
Zevalin iIbritumomab tiuxetan Non-Hodgkin’s Lymphoma (NHL) Unable to recommend reimbursement Not filed
Zytiga (Resubmission) Abiraterone Prostate Cancer Resubmission Withdrawn
TBD Entrectinib Withdrawn
Latuda lurasidone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Imbruvica ibrutinib Leukemia Unable to recommend reimbursement Not filed
Atriance Nelarabine Cancelled
TBC ravulizumab Paroxysmal nocturnal hemoglobinuria. Withdrawn
Demylocan decitabine Myelodysplastic Syndromes Unable to recommend reimbursement Not filed
Xarelto Rivaroxaban (granules for oral suspension) Venous Thromboembolic Events CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
TBC abaloparatide Osteoporosis, postmenopausal women Withdrawn
TBC tirzepatide Diabetes mellitus, type 2 Cancelled
Ikervis cyclosporine keratitis, severe Withdrawn
Breo Ellipta fluticasone furoate/vilanterol COPD Withdrawn
TBD Cabozantinib Withdrawn
Inlyta (RFA) Axitinib Metastatic Renal Cell Carcinoma N/A Complete